Placebo-controlled pharmacological trials in child and adolescents with bipolar disorder manic episode (BPD-ME): Systematic review, meta-analysis and a meta-regression on placebo response

Creative Commons License

Ciray R. O., Hancer P., Tuncturk M., Emiroglu N. I.

KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, cilt.23, sa.3, ss.375-385, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5505/kpd.2020.45822
  • Dergi Adı: KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Psycinfo, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.375-385
  • Anahtar Kelimeler: Pediatric Bipolar Disorder, placebo response, meta-analysis, child and adolescent, DOUBLE-BLIND, I DISORDER, CLINICAL-TRIALS, MIXED EPISODE, ARIPIPRAZOLE, PERSPECTIVE, RISPERIDONE, EFFICACY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Randomized placebo controlled trials (RCT) are very important for testing efficacy and safety of a medical treatment. There is no too much RCT's in childhood bipolar disorder manic episode. In these trials, high placebo response poses a problem for the definition of real drug responses in practice. Therefore, analysis of predictors of drug and placebo response are important for conducting more reliable RCT's in the future. Comprehensive search conducted in PubMed, Clinical Trials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) and some other electronic databases. Studies including participants with Bipolar Disorder manic episode and associated symptoms (e.g ADHD, irritability) included. There was no restriction in terms of sex, ethnicity or initial severity. Participants over age 18 were excluded. Random effect size model was used for calculate effect sizes for placebo and drugs.